Home LiteratureArticle Details
PMID: 9528833 Published · ppublish English Comparative Study Journal Article

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

British journal of cancer ·Vol. 77 ·No. 6 ·1998-03-00 ·Pages 907-12

Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K, Higashino K

Abstract

The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.

MeSH Terms
Adenocarcinoma/blood,pathology Biomarkers, Tumor/analysis,blood C-Reactive Protein/analysis Diagnosis, Differential Fibrinogen/analysis Humans Interleukin-6/analysis,blood Lung Neoplasms/blood,pathology Mesothelioma/blood,drug therapy,mortality,pathology Orosomucoid/analysis Pleural Effusion/blood,chemistry Pleural Neoplasms/blood,drug therapy,mortality,pathology Pleurisy/blood,complications Survival Analysis Tuberculosis, Pulmonary/blood,complications Tumor Necrosis Factor-alpha/analysis
Chemicals
Biomarkers, Tumor Interleukin-6 Orosomucoid Tumor Necrosis Factor-alpha Fibrinogen C-Reactive Protein
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Nakano T
Third Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Chahinian A P
Shinjo M
Tonomura A
Miyake M
Togawa N
Ninomiya K
Higashino K
References (33)
33 references, click to expand
  1. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.
    J Invest Dermatol. 1991 Oct;97(4):686-92 PMID: 1940439
  2. Interleukin-6-producing pheochromocytoma.
    Acta Haematol. 1991;85(4):217-9 PMID: 1853686
  3. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature.
    Int J Cancer. 1992 May 8;51(2):296-301 PMID: 1373705
  4. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Cancer Res. 1992 Jun 15;52(12):3317-22 PMID: 1596890
  5. The evidence for interleukin-6 as an autocrine growth factor in malignancy.
    Semin Cancer Biol. 1992 Feb;3(1):17-26 PMID: 1643291
  6. Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis.
    Cancer. 1992 Oct 15;70(8):2105-8 PMID: 1394040
  7. Acute-phase proteins and interleukin 6 serum level in head and neck cancer.
    Arch Otolaryngol Head Neck Surg. 1992 Dec;118(12):1366-7 PMID: 1280441
  8. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
    Br J Cancer. 1994 May;69(5):911-3 PMID: 8180022
  9. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
    Cancer Res. 1994 Aug 15;54(16):4419-23 PMID: 8044791
  10. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.
    Cancer Immunol Immunother. 1995 Apr;40(4):241-50 PMID: 7750122
  11. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model.
    J Interferon Cytokine Res. 1995 Mar;15(3):213-23 PMID: 7584666
  12. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
    Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201 PMID: 2104241
  13. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
    Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 PMID: 7091938
  14. Thrombocytosis in patients with malignant pleural mesothelioma.
    Cancer. 1986 Oct 15;58(8):1699-701 PMID: 3019510
  15. Serum levels of interleukin-6 and acute phase responses.
    Lancet. 1987 Oct 17;2(8564):921 PMID: 2889120
  16. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma.
    Int J Cancer. 1988 Feb 15;41(2):218-23 PMID: 3276635
  17. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.
    Nature. 1988 Mar 3;332(6159):83-5 PMID: 3258060
  18. Induction of rat acute-phase proteins by interleukin 6 in vivo.
    Eur J Immunol. 1988 May;18(5):717-21 PMID: 2454191
  19. The role of tumor necrosis factor (cachectin) in cachexia.
    Cell. 1988 Jul 15;54(2):141-2 PMID: 3292054
  20. Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody.
    Cancer. 1989 Apr 1;63(7):1331-6 PMID: 2646006
  21. The biology of interleukin-6.
    Blood. 1989 Jul;74(1):1-10 PMID: 2473791
  22. A possible autocrine role for interleukin-6 in two lymphoma cell lines.
    Blood. 1989 Aug 1;74(2):798-804 PMID: 2787680
  23. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
    J Clin Oncol. 1989 Aug;7(8):1157-68 PMID: 2666592
  24. Interleukin-6 is a potent thrombopoietic factor in vivo in mice.
    Blood. 1989 Sep;74(4):1241-4 PMID: 2788464
  25. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
    J Clin Invest. 1989 Dec;84(6):2008-11 PMID: 2592570
  26. Thrombopoietic activity of human interleukin-6.
    FEBS Lett. 1990 Jan 29;260(2):176-8 PMID: 2298297
  27. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.
    Proc Natl Acad Sci U S A. 1990 Apr;87(8):3092-6 PMID: 1691500
  28. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.
    Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72 PMID: 1693429
  29. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6.
    Hepatology. 1990 Nov;12(5):1179-86 PMID: 1699862
  30. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Cancer. 1991 Feb 1;67(3):655-62 PMID: 1702354
  31. Thrombocytosis in malignant pleural mesothelioma.
    Tumori. 1990 Dec 31;76(6):576-8 PMID: 2178286
  32. Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients.
    Surgery. 1991 Jun;109(6):761-7 PMID: 2042096
  33. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients.
    Eur J Clin Invest. 1991 Oct;21(5):479-84 PMID: 1752286
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
1998-03-00
Pages
907-12
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2150109
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com